Summary
- Profile Type
- Technology offer
- POD Reference
- TODE20240611018
- Term of Validity
- 12 June 2024 - 12 June 2025
- Company's Country
- Germany
- Type of partnership
- Investment agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- An invention by a German university offers an efficient therapeutic potential of activated T cells and CAR-T cells for the treatment of cancer, especially solid tumours. The university is offering access to the rights for method development and commercial utilisation of this invention.
- Full Description
-
The concept and advantages of T cells with synthetic antigen-specific T cell receptors (CAR-T cells) are well known in the art and have become a focus of pharmaceutical research and development in recent years. CAR T cells are therapeutically used in individual medicine for the treatment of cancers such as acute lymphoblastic leukemia and B cell lymphomas. However, the success of these therapies has not yet extended to solid tumors. Solid tumors pose a therapeutic challenge as they generate an immunosuppressive milieu that limits the survival and functionality of immune cells. Therefore, key features which could enable the successful treatment of solid tumors, would be improving the survival and functionality of CAR T cells in the tumor microenvironment.
The invention of a German university is to use a new combination of supplements to stimulate isolated T cells from a patient. T cells or prepared CAR T cells are incubated in a medium comprising the supplements of anti-TCRβ, anti-CD28, IL-2 and an additional inventive cocktail of cytokines. This combination not only leaves an individual activation profile on the cells which can be detected using standard technical methods, but also provides a suitable stimulus for improving the expansion, persistence, and functionality of the cells for tumor therapy, in particular of solid tumors.
The university offers an access to rights for method development and commercial use of this invention to companies of the pharmaceutical industry. This invention also adresses producers of therapeutic supplements or T Cell and immunotherapy cultures. - Advantages and Innovations
-
. Strong activation and prevention of exhaustion of T cells and CAR T cells
. High specific cytotoxicity and survival rate of activated T cells and CAR T cells
. Efficient therapeutic potential of activated T cells and CAR T cells for the treatment of cancer, especially of solid tumors - Stage of Development
- Lab tested
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
- IPR notes
- A European patent application has been filed.
Partner Sought
- Expected Role of a Partner
- The university offers an access to rights for method development and commercial use of this invention to companies of the pharmaceutical industry. This invention also adresses producers of therapeutic supplements or T Cell and immunotherapy cultures.
- Type and Size of Partner
- Big company
- SME 11-49
- Other
- SME 50 - 249
- SME <=10
- Type of partnership
- Investment agreement
Dissemination
- Technology keywords
- 06001012 - Medical Research
- 06001003 - Cytology, Cancerology, Oncology
- 06001015 - Pharmaceutical Products / Drugs
- Market keywords
- 05007002 - Pharmaceuticals/fine chemicals
- 05005014 - Oncology
- Targeted countries
- All countries
